このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

A Study of Eltrombopag or Placebo in Combination With Azacitidine in Subjects With International Prognostic Scoring System (IPSS) Intermediate-1, Intermediate-2 or High-risk Myelodysplastic Syndromes (MDS)

2017年11月12日 更新者：Novartis Pharmaceuticals

A Randomized, Double-blind, Placebo-controlled, Phase III, Multi-centre Study of Eltrombopag or Placebo in Combination With Azacitidine in Subjects With IPSS Intermediate-1, Intermediate 2 and High-risk Myelodysplastic Syndromes (MDS) SUPPORT: A StUdy of eltromboPag in myelodysPlastic SyndrOmes Receiving azaciTidine

Eltrombopag olamine (SB-497115-GR) is an orally bioavailable, small molecule thrombopoietin receptor agonist that may be beneficial in medical disorders associated with thrombocytopenia. Eltrombopag has been shown to increase platelet counts in patients with thrombocytopenia from various etiologies (Idiopathic thrombocytopenic purpura [ITP], liver disease, aplastic anemia and chemotherapy induced thrombocytopenia). Approximately 350 subjects will be randomized in a 1:1 ratio (175 into the eltrombopag arm and 175 into the placebo arm). Approximately 55 subjects will be enrolled into the azacitidine. Subjects with intermediate-1, intermediate-2 or high risk MDS by IPSS, and baseline platelet count of <75 Giga (10^9) per liter (Gi/L) will only be enrolled. This is a randomized, double-blind, parallel group, placebo-controlled study designed to explore the platelet supportive care effects of eltrombopag versus placebo in combination with the standard of care hypomethylating agent, azacitidine. The primary objective of this study is to determine the effect of eltrombopag versus placebo on the proportion of subjects who are platelet transfusion free during the first 4 cycles of azacitidine therapy. Key secondary endpoints include overall survival, disease response, and disease progression.

調査の概要

状態

終了しました

条件

介入・治療

研究の種類

介入

入学 (実際)

356

段階

  • フェーズ 3

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究場所

  • アイルランド
      • Dublin、アイルランド、7
        • Novartis Investigative Site
      • Galway、アイルランド
        • Novartis Investigative Site
      • James Street、アイルランド、8
        • Novartis Investigative Site
      • Limerick、アイルランド
        • Novartis Investigative Site
      • Tallaght, Dublin、アイルランド、24
        • Novartis Investigative Site
  • アメリカ
    • Connecticut
      • Hartford、Connecticut、アメリカ、06105
        • Novartis Investigative Site
    • Georgia
      • Atlanta、Georgia、アメリカ、30322
        • Novartis Investigative Site
    • Illinois
      • Chicago、Illinois、アメリカ、60612
        • Novartis Investigative Site
    • Indiana
      • Anderson、Indiana、アメリカ、46016
        • Novartis Investigative Site
    • Missouri
      • Kansas City、Missouri、アメリカ、64128
        • Novartis Investigative Site
      • San Luis、Missouri、アメリカ、63110
        • Novartis Investigative Site
    • New York
      • Bronx、New York、アメリカ、10461
        • Novartis Investigative Site
    • North Carolina
      • Winston-Salem、North Carolina、アメリカ、27157
        • Novartis Investigative Site
    • Washington
      • Seattle、Washington、アメリカ、98108
        • Novartis Investigative Site
    • Wisconsin
      • Milwaukee、Wisconsin、アメリカ、53226
        • Novartis Investigative Site
  • アルゼンチン
      • Ciudad Autonoma de Buenos Aires、アルゼンチン、1114
        • Novartis Investigative Site
      • Ciudad Autonoma de Buenos Aires、アルゼンチン、1425
        • Novartis Investigative Site
      • Ciudad Autonoma de Buenos Aires、アルゼンチン、C1181ACH
        • Novartis Investigative Site
      • Santa Fe、アルゼンチン、S3000ADL
        • Novartis Investigative Site
  • イスラエル
      • Haifa、イスラエル、31096
        • Novartis Investigative Site
      • Holon、イスラエル、58100
        • Novartis Investigative Site
      • Jerusalem、イスラエル、91120
        • Novartis Investigative Site
      • Jerusalem、イスラエル、91031
        • Novartis Investigative Site
      • Kfar Saba、イスラエル、44281
        • Novartis Investigative Site
      • Petach-Tikva、イスラエル、49100
        • Novartis Investigative Site
      • Tel Aviv、イスラエル、64239
        • Novartis Investigative Site
  • イタリア
    • Calabria
      • Reggio Calabria、Calabria、イタリア、89100
        • Novartis Investigative Site
    • Emilia-Romagna
      • Modena、Emilia-Romagna、イタリア、41124
        • Novartis Investigative Site
    • Liguria
      • Genova、Liguria、イタリア、10126
        • Novartis Investigative Site
    • Piemonte
      • Novara、Piemonte、イタリア、28100
        • Novartis Investigative Site
    • Toscana
      • Firenze、Toscana、イタリア、50134
        • Novartis Investigative Site
  • オーストラリア
    • New South Wales
      • Kogarah、New South Wales、オーストラリア、2217
        • Novartis Investigative Site
    • South Australia
      • Adelaide、South Australia、オーストラリア、5000
        • Novartis Investigative Site
    • Victoria
      • Clayton、Victoria、オーストラリア、3168
        • Novartis Investigative Site
      • East Melbourne、Victoria、オーストラリア、3002
        • Novartis Investigative Site
      • Melbourne、Victoria、オーストラリア、3000
        • Novartis Investigative Site
  • オーストリア
      • Graz、オーストリア、8036
        • Novartis Investigative Site
      • Innsbruck、オーストリア、A-6020
        • Novartis Investigative Site
      • Linz、オーストリア、4020
        • Novartis Investigative Site
      • Rankweil、オーストリア、A-6830
        • Novartis Investigative Site
      • Salzburg、オーストリア、A-5020
        • Novartis Investigative Site
      • Steyr、オーストリア、4400
        • Novartis Investigative Site
      • Vienna、オーストリア、1140
        • Novartis Investigative Site
  • カナダ
      • Quebec、カナダ、G1J 1Z4
        • Novartis Investigative Site
      • Québec、カナダ、G1J 1Z4
        • Novartis Investigative Site
    • Ontario
      • Toronto、Ontario、カナダ、M5G 2M9
        • Novartis Investigative Site
    • Quebec
      • Montreal、Quebec、カナダ、H2L 4M1
        • Novartis Investigative Site
      • Sherbrooke、Quebec、カナダ、J1H 5N4
        • Novartis Investigative Site
  • ギリシャ
      • Athens,、ギリシャ、11 527
        • Novartis Investigative Site
      • Larisa、ギリシャ、41 110
        • Novartis Investigative Site
      • Patra、ギリシャ、26500
        • Novartis Investigative Site
      • Thessaloniki、ギリシャ、54642
        • Novartis Investigative Site
      • Thessaloniki、ギリシャ、54636
        • Novartis Investigative Site
  • スイス
      • Aarau、スイス、5001
        • Novartis Investigative Site
      • Bellinzona、スイス、6500
        • Novartis Investigative Site
      • Bern、スイス、3010
        • Novartis Investigative Site
      • Zuerich、スイス、8091
        • Novartis Investigative Site
  • スウェーデン
      • Goteborg、スウェーデン、SE-413 45
        • Novartis Investigative Site
      • Göteborg、スウェーデン、SE-413 45
        • Novartis Investigative Site
      • Stockholm、スウェーデン、SE-141 86
        • Novartis Investigative Site
      • Uppsala、スウェーデン、SE-751 85
        • Novartis Investigative Site
  • スペイン
      • Barcelona、スペイン、08035
        • Novartis Investigative Site
      • Barcelona、スペイン、08036
        • Novartis Investigative Site
      • Gerona、スペイン、17007
        • Novartis Investigative Site
      • La Laguna (Santa Cruz De Tenerife)、スペイン、38320
        • Novartis Investigative Site
      • Leon、スペイン、24071
        • Novartis Investigative Site
      • León、スペイン、24071
        • Novartis Investigative Site
      • Madrid、スペイン、28034
        • Novartis Investigative Site
      • Madrid、スペイン、28046
        • Novartis Investigative Site
      • Madrid、スペイン、28007
        • Novartis Investigative Site
      • Majadahonda (Madrid)、スペイン、28222
        • Novartis Investigative Site
      • Malaga、スペイン、29010
        • Novartis Investigative Site
      • Málaga、スペイン、29010
        • Novartis Investigative Site
      • Oviedo、スペイン、33006
        • Novartis Investigative Site
      • Palma de Mallorca、スペイン、07198
        • Novartis Investigative Site
      • Palma de Mallorca、スペイン、07014
        • Novartis Investigative Site
      • Pozuelo De Alarcon/Madrid、スペイン、28223
        • Novartis Investigative Site
      • Pozuelo De Alarcón/Madrid、スペイン、28223
        • Novartis Investigative Site
      • Salamanca、スペイン、37007
        • Novartis Investigative Site
      • Valencia、スペイン、46026
        • Novartis Investigative Site
      • Valencia、スペイン、46010
        • Novartis Investigative Site
    • Asturias
      • Oviedo、Asturias、スペイン、33011
        • Novartis Investigative Site
  • タイ
      • Bangkok、タイ、10700
        • Novartis Investigative Site
      • Bangkok、タイ、10400
        • Novartis Investigative Site
      • ChiangMai、タイ、50000
        • Novartis Investigative Site
  • チェコ
      • Brno、チェコ、625 00
        • Novartis Investigative Site
      • Ostrava、チェコ、708 52
        • Novartis Investigative Site
      • Praha、チェコ、128 20
        • Novartis Investigative Site
      • Praha 10、チェコ、100 34
        • Novartis Investigative Site
      • Praha 2、チェコ、128 08
        • Novartis Investigative Site
  • デンマーク
      • Aarhus、デンマーク、8000 C
        • Novartis Investigative Site
      • Koebenhavn Oe、デンマーク、2100
        • Novartis Investigative Site
  • ドイツ
    • Baden-Wuerttemberg
      • Stuttgart、Baden-Wuerttemberg、ドイツ、70199
        • Novartis Investigative Site
    • Bayern
      • Muenchen、Bayern、ドイツ、81675
        • Novartis Investigative Site
    • Niedersachsen
      • Goettingen、Niedersachsen、ドイツ、37075
        • Novartis Investigative Site
    • Nordrhein-Westfalen
      • Duesseldorf、Nordrhein-Westfalen、ドイツ、40225
        • Novartis Investigative Site
      • Duesseldorf、Nordrhein-Westfalen、ドイツ、40479
        • Novartis Investigative Site
      • Duisburg、Nordrhein-Westfalen、ドイツ、47166
        • Novartis Investigative Site
    • Sachsen
      • Dresden、Sachsen、ドイツ、01307
        • Novartis Investigative Site
  • ノルウェー
      • Bergen、ノルウェー、N-5021
        • Novartis Investigative Site
      • Oslo、ノルウェー、0027
        • Novartis Investigative Site
  • ハンガリー
      • Debrecen、ハンガリー、4012
        • Novartis Investigative Site
      • Szeged、ハンガリー、6725
        • Novartis Investigative Site
  • フランス
      • Angers Cedex 9、フランス、49933
        • Novartis Investigative Site
      • Caen Cedex 9、フランス、14033
        • Novartis Investigative Site
      • Le Mans、フランス、72000
        • Novartis Investigative Site
      • Paris、フランス、75010
        • Novartis Investigative Site
      • Paris Cedex 12、フランス、75571
        • Novartis Investigative Site
      • Pringy Cedex、フランス、74374
        • Novartis Investigative Site
  • ブラジル
      • Rio de Janeiro、ブラジル、20211-030
        • Novartis Investigative Site
      • Sao Paulo - SP、ブラジル、01323-900
        • Novartis Investigative Site
    • Minas Gerais
      • Belo Horizonte、Minas Gerais、ブラジル、30130-100
        • Novartis Investigative Site
    • Paraná
      • Curitiba、Paraná、ブラジル、81520-060
        • Novartis Investigative Site
    • Rio Grande Do Sul
      • Porto Alegre、Rio Grande Do Sul、ブラジル、90035-903
        • Novartis Investigative Site
    • Santa Catarina
      • Florianopolis、Santa Catarina、ブラジル、88034-000
        • Novartis Investigative Site
    • São Paulo
      • Sao Paulo、São Paulo、ブラジル、01236030
        • Novartis Investigative Site
      • Sao Paulo、São Paulo、ブラジル、08270-070
        • Novartis Investigative Site
  • プエルトリコ
      • San Juan、プエルトリコ、00927
        • Novartis Investigative Site
  • ベルギー
      • Brasschaat、ベルギー、2930
        • Novartis Investigative Site
      • Brugge、ベルギー、8000
        • Novartis Investigative Site
      • Leuven、ベルギー、3000
        • Novartis Investigative Site
      • Lodelinsart、ベルギー、6042
        • Novartis Investigative Site
      • Turnhout、ベルギー、2300
        • Novartis Investigative Site
  • ペルー
      • Lima、ペルー、Lima 11
        • Novartis Investigative Site
      • Lima、ペルー、Lima 31
        • Novartis Investigative Site
  • ポーランド
      • Krakow、ポーランド、31-501
        • Novartis Investigative Site
      • Legnica、ポーランド、59-200
        • Novartis Investigative Site
      • Lublin、ポーランド、20-081
        • Novartis Investigative Site
      • Opole、ポーランド、45-061
        • Novartis Investigative Site
      • Slupsk、ポーランド、76-200
        • Novartis Investigative Site
      • Torun、ポーランド、87-100
        • Novartis Investigative Site
  • メキシコ
      • Oaxaca、メキシコ、68000
        • Novartis Investigative Site
    • Nuevo León
      • Monterrey、Nuevo León、メキシコ、64460
        • Novartis Investigative Site
  • ロシア連邦
      • Kaluga、ロシア連邦、248007
        • Novartis Investigative Site
      • Moscow、ロシア連邦、115478
        • Novartis Investigative Site
      • Moscow、ロシア連邦、125167
        • Novartis Investigative Site
      • Moscow、ロシア連邦、129301
        • Novartis Investigative Site
      • Penza、ロシア連邦、440071
        • Novartis Investigative Site
      • St Petersburg、ロシア連邦、193024
        • Novartis Investigative Site
      • St'Petersburg、ロシア連邦、197341
        • Novartis Investigative Site
  • 七面鳥
      • Ankara、七面鳥、06590
        • Novartis Investigative Site
      • Izmir、七面鳥、35340
        • Novartis Investigative Site
      • Izmir、七面鳥、35100
        • Novartis Investigative Site
      • Samsun、七面鳥、55139
        • Novartis Investigative Site
  • 台湾
      • Changhua、台湾、500
        • Novartis Investigative Site
      • Kaohsiung、台湾、807
        • Novartis Investigative Site
      • Kaohsiung、台湾、833
        • Novartis Investigative Site
      • Taipei、台湾、112
        • Novartis Investigative Site
  • 大韓民国
      • Seoul、大韓民国、06351
        • Novartis Investigative Site
      • Seoul、大韓民国、138-736
        • Novartis Investigative Site
      • Seoul、大韓民国、135-710
        • Novartis Investigative Site
      • Seoul、大韓民国、137-701
        • Novartis Investigative Site
      • Seoul、大韓民国、06591
        • Novartis Investigative Site
      • Seoul、大韓民国、05505
        • Novartis Investigative Site
  • 香港
      • Chai Wan、香港
        • Novartis Investigative Site
      • Hong Kong、香港
        • Novartis Investigative Site
      • Shatin, New Territories、香港
        • Novartis Investigative Site
      • Tuen Mun、香港
        • Novartis Investigative Site

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年歳以上 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria:

  • Age >=18 years (For subjects in Taiwan, Age >= 20 years)
  • MDS by World Health Organization (WHO) or French-American-British (FAB) classification
  • Intermediate 1, intermediate 2 or high risk MDS by IPSS
  • At least one platelet count < 75 Gi/L
  • Eastern Cooperative Oncology Group (ECOG) Status 0-2
  • Adequate baseline organ function defined by the criteria below: total bilirubin =< 1.5x the upper limit of normal (ULN) except for Gilbert's syndrome or cases clearly not indicative of inadequate liver function (i.e. elevation of indirect [haemolytic] bilirubin in the absence of alanine aminotransferase [ALT] abnormality); ALT =< 2.5xULN; creatinine =< 2.5xULN
  • Subjects with a corrected QT interval (QTc) <450 milliseconds (msec) or <480msec for subjects with bundle branch block. The QTc is the QT interval corrected for heart rate according to Fridericia's formula (QTcF), machine or manual overread. For subject eligibility and withdrawal, QTcF will be used. For purposes of data analysis, QTcF will be used. The QTc should be based on single or averaged QTc values of triplicate electrocardiograms (ECGs) obtained over a brief recording period
  • Subject is able to understand and comply with protocol requirements and instructions
  • Subject has signed and dated informed consent
  • Women must be either of non-child bearing potential, or women with child-bearing potential and men with reproductive potential must be willing to practice acceptable methods of birth control during the study
  • Women of childbearing potential must have a negative serum or urine pregnancy test within 7 days of first dose of study treatment and agree to use effective contraception during the study and for 3 months following the last dose of study treatment
  • Men with a female partner of childbearing potential must have either had a prior vasectomy or agree to use effective contraception from time of randomization until 16 weeks after the last dose of study treatment
  • French subjects: In France, a subject will be eligible for inclusion in this study only if either affiliated to or a beneficiary of a social security category

Exclusion Criteria:

  • Previous treatment with hypomethylating agent or induction chemotherapy for MDS
  • Proliferative type chronic myelomonocytic leukemia with white blood cell count >12 Gi/L at any time during the 28 days before Day 1
  • History of treatment with eltrombopag, romiplostim or other thrombopoietin receptor (TPO-R) agonists
  • Previous allogeneic stem-cell transplantation
  • Known thrombophilic risk factors. Exception: Subjects for whom the potential benefits of participating in the study outweigh the potential risks of thromboembolic events, as determined by the investigator
  • Treatment with an investigational drug within 30 days or 5 half-lives (whichever is longer) preceding the first dose of investigational product (eltrombopag/placebo)
  • Active and uncontrolled infections, including hepatitis B or C
  • Human Immunodeficiency Virus (HIV) infection
  • Known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to eltrombopag or its excipient, or azacitidine, that contraindicates the subjects' participation
  • Pregnant or lactating female
  • Any serious and/or unstable pre-existing medical condition (including any advanced malignancy other than the disease under study), psychiatric disorder, or other conditions that could interfere with subject's safety, obtaining informed consent or compliance with the study procedures
  • French subjects: the French subject has participated in any study using an investigational drug during the previous 30 days

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか？

デザインの詳細

  • 主な目的：処理
  • 割り当て：ランダム化
  • 介入モデル：並列代入
  • マスキング：ダブル

武器と介入

参加者グループ / アーム
介入・治療
実験的：Eltrombopag
Eligible subject will receive a starting dose of eltrombopag of 200 milligrams (mg) (100 mg for subjects of East Asian heritage). Dose modifications of eltrombopag will be permitted by 100 mg increments (50 mg increments for East Asians) to a lowest dose of 100 mg (50 mg for East Asian heritage) or a maximum dose of 300 mg (150 mg for East Asian heritage) in order to maintain platelet counts at a safe and effective level (i.e. a level sufficient to avoid platelet transfusions and bleeding events). Subjects will receive azacitidine 75 mg/meter^2 subcutaneously once daily for 7 days (+/- 3 day treatment window permitted) every 28 days, for at least 6 cycles if tolerated and until they are no longer receiving benefit (defined as at least stable disease per the investigator's assessment) or until disease progression, death, or unacceptable toxicity/adverse event. The subject may receive eltrombopag daily for the full 28 days each cycle for as long as the subject is receiving azacitidine
薬：Eltrombopag
Eltrombopag will be round film-coated tablets containing eltrombopag equivalent to 50 mg (white to off-white), 200 mg and 300 mg (green) of eltrombopag free acid
薬：Azacitidine
Subcutaneous Injection (IV if local standard)
プラセボコンパレーター：Placebo
Eligible subject will receive eltrombopag matching placebo. Subjects will receive azacitidine 75 mg/meter^2 subcutaneously once daily for 7 days (+/- 3 day treatment window permitted) every 28 days, for at least 6 cycles if tolerated and until they are no longer receiving benefit (defined as at least stable disease per the investigator's assessment) or until disease progression, death, or unacceptable toxicity/adverse event. The subject may receive eltrombopag daily for the full 28 days each cycle for as long as the subject is receiving azacitidine
薬：Azacitidine
Subcutaneous Injection (IV if local standard)
薬：Placebo
Eltrombopag matching placebo tablets
薬：Placebo
Eltrombopag matching placebo tablets will be supplied

この研究は何を測定していますか？

主要な結果の測定

結果測定
メジャーの説明
時間枠
Number of Participants Who Were Platelet Transfusion Independent During Cycles 1-4 of Azacitidine Therapy
時間枠：4 cycles (Cycle = 28 days)
A subject is defined as being platelet transfusion independent if they received no platelet transfusions within the first 4 cycles of treatment with azacitidine. Subjects who died or withdrew from investigational product within the first four cycles were treated as failures (i.e. not transfusion independent) in the analysis
4 cycles (Cycle = 28 days)

二次結果の測定

結果測定
メジャーの説明
時間枠
Overall Survival (OS)
時間枠：Randomization until death or end of study, approximately 2 years
Overall survival is defined as the time from randomization until death due to any cause and deaths have been presented. Subjects still alive at the time of the analysis and subjects who have withdrawn from the study will be censored at the time of last contact
Randomization until death or end of study, approximately 2 years
Summary of Progression Free Survival From Investigator Assessment (ITT)
時間枠：First day of each cycle (Cycles 3+), at the end of therapy visit and every 3 months in follow-up for approximately 2 years
Progression-free survival, defined as the time from randomization until either disease progression or death. The modified 2006 IWG criteria for MDS used for progression assessment For patients with: Less than 5% BM blasts: ≥ 50% increase in blasts to > 5% blasts; 5% - <10% BM blasts: ≥ 50% increase to > 10% blasts; 10% - <20% BM blasts: ≥ 50% increase to > 20% blasts; 20% - 30% BM blasts: ≥ 50% increase to > 30% blasts
First day of each cycle (Cycles 3+), at the end of therapy visit and every 3 months in follow-up for approximately 2 years
Summary of Progression Free Survival From Central Review (ITT)
時間枠：First day of each cycle (Cycles 3+), at the end of therapy visit and every 3 months in follow-up for approximately 2 years

Progression-free survival, defined as the time from randomization until either disease progression or death. The modified 2006 IWG criteria for MDS used for progression assessment For patients with:

Less than 5% BM blasts: ≥ 50% increase in blasts to > 5% blasts; 5% - <10% BM blasts: ≥ 50% increase to > 10% blasts; 10% - <20% BM blasts: ≥ 50% increase to > 20% blasts; 20% - 30% BM blasts: ≥ 50% increase to > 30% blasts
First day of each cycle (Cycles 3+), at the end of therapy visit and every 3 months in follow-up for approximately 2 years
Summary of AML Progression From Investigator Assessment and Central Review (ITT)
時間枠：First day of each cycle (Cycles 3+), at the end of therapy visit and every 3 months in follow-up for approximately 2 years

Progression to AML in MDS patients with baseline bone marrow blast < 20% was defined as meeting definition of disease progression according to the modified 2006 IWG response criteria for MDS with the additional requirement that bone marrow blast or peripheral blast increases from < 20% at baseline to ≥ 20% postbaseline. Progression assessment For patients with:

Less than 5% BM blasts: ≥ 50% increase in blasts to > 5% blasts; 5% - <10% BM blasts: ≥ 50% increase to > 10% blasts; 10% - <20% BM blasts: ≥ 50% increase to > 20% blasts; 20% - 30% BM blasts: ≥ 50% increase to > 30% blasts
First day of each cycle (Cycles 3+), at the end of therapy visit and every 3 months in follow-up for approximately 2 years
Best Disease Response From Investigator Assessment (ITT)
時間枠：At end of Cycle 6 (cycle=28 days) or end of therapy, whichever came first
Best disease response is categorized as complete remission (CR), partial remission (PR), or marrow CR, stable disease, disease progression, or as non-evaluable; according to modified 2006 International Working Group (IWG) criteria for MDS
At end of Cycle 6 (cycle=28 days) or end of therapy, whichever came first
Best Disease Response From Central Review (ITT)
時間枠：At end of Cycle 6 (cycle=28 days) or end of therapy, whichever came first
Best disease response is categorized as complete remission (CR), partial remission (PR), or marrow CR, stable disease, disease progression, or as non-evaluable; according to modified 2006 International Working Group (IWG) criteria for MDS
At end of Cycle 6 (cycle=28 days) or end of therapy, whichever came first
Hematologic Improvement (HI) in Platelets, Neutrophils, and Hemoglobin Based on the Modified IWG Criteria for MDS (ITT)
時間枠：From Day 1 to 4-week follow-up (samples collected weekly in Cycle 1, Days 1 and 15 in Cycles 2-6 and Day 1 of Cycles >=7)
HI based on the modified IWG criteria for MDS. HI - Platelets (BL <100Gi/L), response criteria= BL <20: increase to>20 and 100% at least for 56 days or BL >=20: absolute increase of >=30. HI - Neutrophils (BL <1.0 Gi/L), response criteria=100% increase and an absolute increase >0.5 Gi/L over BL for at least 56 days. HI-Hemoglobin (BL <g/dL), response criteria=Hgb increase by >=1.5 g/dL over BL, RBC transfusions(given for Hgb<=9.0) reduced by >=4 per 8w from BL
From Day 1 to 4-week follow-up (samples collected weekly in Cycle 1, Days 1 and 15 in Cycles 2-6 and Day 1 of Cycles >=7)
Number of Participants Who Were Platelet Transfusion Independent (ITT Set)
時間枠：From Day 1 to end of study treatment up to approximately 2 years
Platelet transfusion independence is defined for each cycle as the number of participants who continue to the end of a cycle without requiring a platelet transfusion
From Day 1 to end of study treatment up to approximately 2 years
Bleeding Adverse Events (AEs) >= Grade 3
時間枠：From Day 1 to 4-week follow-up up to approximately 2 years
Bleeding will be assessed by recording AEs or serious adverse events (SAEs) as graded according to National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) v4.0
From Day 1 to 4-week follow-up up to approximately 2 years
Number of of Subjects With Azacitidine Dose Delays, Dose Reductions, Interruptions
時間枠：From Day 1 to 4-week follow-up up to approximately 2 years
The proportion of subjects with any delay, reduction or interruption in dosage of Azacitidine excluding those for non-medical reasons will be analyzed
From Day 1 to 4-week follow-up up to approximately 2 years
Response Levels in All Domains of Euroquol-5 Dimensions of Health, 3 Response Levels (EQ-5D-3L™)
時間枠：From Day 1 to 4-week follow-up up to approximately 2 years
The EQ-5D is a general health status and health utility measure which captures 5 dimensions of health state: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. (EQ-5D is a trademark of the Stichting EuroQol Group) . C=cycle, D=Day
From Day 1 to 4-week follow-up up to approximately 2 years
Functional Assessment of Chronic Disease Therapy-fatigue Subscale (FACIT-Fatigue) (ITT)
時間枠：From Day 1 to 4-week follow-up (Approximate median 9 Cycles+4 weeks follow-up) up to approximately 2 years
The FACIT-Fatigue subscale measures severity and impact of fatigue on functioning and Health Related QoL experienced in the past 7 days. Scale is a 13 item measure of fatigure. Items are scored on a 0-4 response scale ranging from "not at all" to "very much so". All items are summed to create a single fatigure score with a range from 0 to 52. Items are reverse scored when appropriate to provide a scale in which higher scores represent better functioning or less fatiigue (The FACIT Fatigue Scale is owned by David Cella, Ph.D.)
From Day 1 to 4-week follow-up (Approximate median 9 Cycles+4 weeks follow-up) up to approximately 2 years
Medical Resource Utilization (MRU): Event -Hospitalizations Inpatient and Outpatient
時間枠：From Day 1 to 4-week follow-up (Approximate median 9 Cycles+4 weeks follow-up) up to approximately 2 years
MRU data will be collected for each subject. Events corresponding to unscheduled (not scheduled per protocol) hospitalizations
From Day 1 to 4-week follow-up (Approximate median 9 Cycles+4 weeks follow-up) up to approximately 2 years
Medical Resource Utilization (MRU): Event and Use of Site Specific Medical Resources - Non-study Laboratory Tests
時間枠：From Day 1 to 4-week follow-up (Approximate median 9 Cycles+4 weeks follow-up) up to approximately 2 years
MRU data will be collected for each subject. Events corresponding to unscheduled (not scheduled per protocol) hospitalizations, office visits including consultations, laboratory and diagnostic tests (lab results, imaging etc.), and procedures prior to therapy initiation and during therapy will be collected
From Day 1 to 4-week follow-up (Approximate median 9 Cycles+4 weeks follow-up) up to approximately 2 years
Medical Resource Utilization (MRU): Use of Site Specific Medical Resources
時間枠：From Day 1 to 4-week follow-up (Approximate median 9 Cycles+4 weeks follow-up) up to approximately 2 years
MRU data will be collected for each subject. Events corresponding to unscheduled (not scheduled per protocol) hospitalizations, office visits including consultations, laboratory and diagnostic tests (lab results, imaging etc.), and procedures prior to therapy initiation and during therapy will be collected
From Day 1 to 4-week follow-up (Approximate median 9 Cycles+4 weeks follow-up) up to approximately 2 years
Summary of Post-Hoc Estimates of Steady-state Eltrombopag Cmax and Cmin Pharmacokinetic Parameters for a 50 mg Dose
時間枠：Cycle 1, Week 2: Pre-dose, 1.5 and 3 hour post dose; Cycle 1, Week 3: 4, 5.5, and 7 hours post dose
Eltrombopag concentrations were analyzed using a population PK model along with data from other studies in healthy volunteers and in patients with MDS and/or AML. Post-hoc PK parameters were derived. Only patients from this study were included (163)
Cycle 1, Week 2: Pre-dose, 1.5 and 3 hour post dose; Cycle 1, Week 3: 4, 5.5, and 7 hours post dose
Summary of Post-Hoc Estimates of Steady-state Eltrombopag AUC0 Infinity Pharmacokinetic Parameters for a 50 mg Dose
時間枠：Cycle 1, Week 2: Pre-dose, 1.5 and 3 hour post dose; Cycle 1, Week 3: 4, 5.5, and 7 hours post dose
Eltrombopag concentrations were analyzed using a population PK model along with data from other studies in healthy volunteers and in patients with MDS and/or AML. Post-hoc PK parameters were derived. Only patients from this study were included (163)
Cycle 1, Week 2: Pre-dose, 1.5 and 3 hour post dose; Cycle 1, Week 3: 4, 5.5, and 7 hours post dose
AUC0-infinity -Pharmacokinetic(s) Parameter of Azacitidine
時間枠：Cycle 2 Day 1: Pre-dose, 15 min, 0.5, 1, 2 and 4 hr post dose
An analysis of variance (ANOVA) on AUC0-infinity. The PK parameters were log transformed prior to analysis. The model included treatment as a fixed effect. Point estimates and their associated 90% CI were constructed for the differences in PK parameter values. The point estimates and their associated 90% CI were then back transformed to provide point estimates and 90% CI for the azacitidine + eltrombopag:azacitidine + placebo PK parameter ratios.
Cycle 2 Day 1: Pre-dose, 15 min, 0.5, 1, 2 and 4 hr post dose
Cmax -Pharmacokinetic Parameter of Azacitidine
時間枠：Cycle 2 Day 1: Pre-dose, 15 min, 0.5, 1, 2 and 4 hr post dose
An analysis of variance (ANOVA) on Cmax . The PK parameters were log transformed prior to analysis. The model included treatment as a fixed effect. Point estimates and their associated 90% CI were constructed for the differences in PK parameter values. The point estimates and their associated 90% CI were then back transformed to provide point estimates and 90% CI for the azacitidine + ltrombopag:azacitidine + placebo PK parameter ratios.
Cycle 2 Day 1: Pre-dose, 15 min, 0.5, 1, 2 and 4 hr post dose

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

Novartis Pharmaceuticals

出版物と役立つリンク

研究に関する情報を入力する責任者は、自発的にこれらの出版物を提供します。これらは、研究に関連するあらゆるものに関するものである可能性があります。

一般刊行物

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2014年6月10日

一次修了 (実際)

2016年4月30日

研究の完了 (実際)

2016年4月30日

試験登録日

最初に提出

2014年6月5日

QC基準を満たした最初の提出物

2014年6月5日

最初の投稿 (見積もり)

2014年6月9日

学習記録の更新

投稿された最後の更新 (実際)

2017年12月12日

QC基準を満たした最後の更新が送信されました

2017年11月12日

最終確認日

2017年9月1日

詳しくは

本研究に関する用語

キーワード

追加の関連 MeSH 用語

その他の研究ID番号

  • 112121

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

はい

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する